Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17782436 | 0.93 | MAPT (0.61) | GAAMAPTRAB9AL3MBTL1KDM4E | |
| SCHEMBL9479693 | 0.93 | ALDH1A1 (0.46) | GAAMAPTRAB9AL3MBTL1KDM4E | |
| SCHEMBL16411847 | 0.93 | ALDH1A1 (0.46) | GAAMAPTRAB9AL3MBTL1KDM4E | |
| SCHEMBL6155918 | 0.93 | PREP (0.44) | GAAMAPTRAB9AL3MBTL1KDM4E | |
| SCHEMBL16411531 | 0.91 | RAD52 (0.44) | GAAMAPTRAB9AL3MBTL1KDM4E | |
| SCHEMBL16411425 | 0.91 | PREP (0.40) | GAAMAPTRAB9AL3MBTL1KDM4E | |
| SCHEMBL16467970 | 0.91 | SCN9A (0.44) | GAAMAPTRAB9AL3MBTL1KDM4E | |
| SCHEMBL16467865 | 0.89 | PREP (0.39) | GAAMAPTRAB9AL3MBTL1KDM4E | |
| SCHEMBL19304598 | 0.88 | PREP (0.38) | GAAMAPTRAB9AL3MBTL1KDM4E | |
| SCHEMBL16467901 | 0.88 | EPHX2 (0.46) | MAPTRAB9AL3MBTL1NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258626-B2 | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2019-04-16 | — | — | US | disclosed |
| US-20170151251-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-06-01 | — | — | US | disclosed |
| US-9603854-B2 | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-03-28 | — | — | US | disclosed |
| EP-2807159-B1 | NEW INDOLIZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF CANCER | SERVIER LAB (FR) | 2016-11-23 | — | — | EP | disclosed |
| US-20150313911-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | VERNALIS (R&D) LTD (GB) | 2015-11-05 | — | — | US | disclosed |
| US-9120791-B2 | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20150051189-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | VERNALIS (R&D) LTD (GB) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313911-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDO1, IDO2, API5 | GAA 4179/4885MAPT 2320/4885RAB9A 903/4885 |
| US-10258626-B2 | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them | IDO1, IDO2, API5 | GAA 4179/4885MAPT 2320/4885RAB9A 903/4885 |
| US-20150051189-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDO1, IDO2, API5 | GAA 4179/4885MAPT 2320/4885RAB9A 903/4885 |
| US-20170151251-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDO1, IDO2, API5 | GAA 4179/4885MAPT 2320/4885RAB9A 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.